Curis (CRIS) Q3 2026 Earnings Call Transcript
Curis (CRIS) reported Q3 2026 net loss of $8.1M, narrower than 2025. The company is advancing clinical trials for emavusertib in NHL and CLL, with initial data expected by year-end. They aim for accelerated approval submissions in 2027. Cash reserves are $5M, expected to fund operations into 2027.
How this was made

The 30-second read
Why it matters
Earnings show narrowing losses and ongoing trial enrollment, which may improve investor sentiment.
Market read
Primary earnings release for a micro‑cap biotech; relevance mainly to sector and CRIS shareholders.
What to watch
Potential regulatory delays for emavusertib and competition from other BTK inhibitor combos.
Background
Curis (CRIS) is a clinical‑stage biotech developing emavusertib for BTK‑resistant cancers.
Ticker impact
Curis reported Q3 2026 net loss of $8.1M ($1.94 per share) and updated clinical trial progress, a fresh earnings disclosure.
likely modest upside as loss per share improves and trial updates may boost confidence
The per‑share loss narrowed sharply from $9.86 to $1.94, indicating better cost control and potential future revenue from emavusertib trials.
Market effects
Biotech sector may see slight uplift as a small‑cap trial update shows progress.
US biotech investors may adjust positions; limited broader market effect.
Minimal global impact beyond niche biotech investors.
Counterpoint
Losses remain sizable; cash runway limited; risk of dilution could outweigh upside.
Key entities
- CompanyCuris
Biotech firm developing emavusertib.
- DrugEmavusertib
Investigational therapy targeting TLR pathway.
